| Literature DB >> 28278728 |
Fie J Vojdeman1,2, Sarah E M Herman3, Nikolai Kirkby4, Adrian Wiestner3, Mars B van T' Veer5, Geir E Tjønnfjord6, Maija A Itälä-Remes7, Eva Kimby8, Mohammed Z Farooqui3, Aaron Polliack9, Ka Lung Wu10, Jeanette K Doorduijn11, Wendimagegn G Alemayehu12, Shulamiet Wittebol13, Tomas Kozak14, Jan Walewski15, Martine C J Abrahamse-Testroote12, Marinus H J van Oers16, Christian H Geisler1, Carsten U Niemann1.
Abstract
CD52 is a glycoprotein expressed on normal as well as leukemic immune cells and shed as soluble CD52 (sCD52). We studied sCD52 levels in three CLL cohorts: the 'early', the 'high-risk', and the 'ibrutinib-treated'. The 'high-risk' patients had significantly higher sCD52 levels than the 'early' patients. For the 'early' patients, high sCD52 levels were associated with a significantly shorter time to first treatment. Regarding prognostic factors, no clear correlations with stage, IGHV, or beta-2-microglobulin were found; in a cox multivariate analysis of the 'early' patients, sCD52 and IGHV both had independent prognostic value. Following chemo-immunotherapy, sCD52 decreased in parallel with leukocytes while during ibrutinib treatment and ibrutinib-induced ymphocytosis, sCD52 decreased along with lymph node reductions. In vitro IgM stimulation of CLL cells led to increased sCD52 levels in the medium. Our findings indicate that sCD52 reflects disease activity and potentially treatment efficacy in CLL.Entities:
Keywords: CD52; CLL; chemo-immunotherapy; ibrutinib
Mesh：
Substances：
Year: 2017 PMID： 28278728 PMCID： PMC6441671 DOI： 10.1080/10428194.2017.1285027
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022